- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01878890
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure. (ESCALE)
Phase I Dose Escalation Trial of Efavirenz for Patients With Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
Hypothesis: encouraging results of phase II study FAVE in the treatment of hormonal resistant prostate cancer lead us to continue clinical development of efavirenz. Furthermore, all available pre-clinical and clinical data lead us to conduct a Phase 1 study with efavirenz. Objective of this Phase I is to test doses above 600 mg / day in patients with cancer in order to determine the maximum tolerated dose to improve therapeutic effect.
This study is a single center Phase I trial, conduct with dose escalation scheme of efavirenz by continual reassessment method likehood approach (CRML) on solid tumours (except pancreatic cancer) and non-Hodgkin lymphoma (NHL).
Main objective is to determine the safety profile, and particularly the maximum tolerated dose of efavirenz for the treatment of patients with solid tumors (except pancreatic cancer) or NHL in therapeutic failure.
Secondary objectives are:
- Evaluate efavirenz pharmacokinetics at 2, 4 and 12 weeks;
- Evaluate objective response at 12 weeks;
- Evaluate progression free survival at 6 months;
- Assess biological progression-free survival at 6 months (prostate tumours only).
Primary Endpoint
Safety will be evaluated according to the toxicity scale NCI-CTCAE v4.0. Dose limiting toxicities will be collected during the first 28 days (+ / - 7 days) after first dose of Efavirenz and will be defined as follows:
- Any drug-related toxicity with grade ≥ 3 according to NCI-CTCAE v4.0 (except alopecia, nausea and vomiting, regardless of grade),
- Any drug-related toxicity, regardless of grade, who led a treatment delay> 14 days,
- Score ≥ 19 HAD during treatment. Secondary Criteria
- Solid tumors: response and progression defined by RECIST v1.1 [Eisenhauer EA et al. EJC 2009).
- Non-Hodgkin lymphomas: Response and progression defined according to Cheson criteria [Cheson BD et al. JCO 1999]
- Biological progression (particular case of prostate tumors): defined according to Scher [Scher HI et al. JCO 2008] Statistical Considerations This is a Phase I dose escalation strategy using the method CRML, described by O'Quigley and Shen [O'Quigley et al. Biometrics 1996] and commonly used in Phase I trials in oncology.
- Maximum number of eligible and evaluable subjects is 30.
- Six dose levels are initially defined: 600 mg, 1200 mg, 1800 mg, 2200 mg, 2600 mg, 3000 mg.
- The risk of dose limiting toxicities maximum allowed is 25%.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase I dose escalation strategy according to the method described by CRML O'Quigley and Shen [O'Quigley et al. Biometrics 1996] and commonly used in phase I trials in oncology.
Six levels of doses are initially defined: 600 mg, 1200 mg, 1800 mg, 2200 mg, 2600 mg, 3000 mg.
The maximum potential dose-limiting toxicities allowed is 25%.
Dose limiting toxicities will be defined as follows:
- Any drug-related toxicity with grade ≥ 3 according to NCI-CTCAE v4.0 (except alopecia, nausea and vomiting, regardless of grade),
- Any drug-related toxicity, regardless of grade, who led a treatment delay> 14 days,
- Score ≥ 19 HAD during treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33076
- Institut Bergonié
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria :
- Patients with solid tumors (except pancreatic cancer) or non-Hodgkin lymphoma
- Metastatic disease or locally advanced inoperable tumor, not accessible to standard therapy.
- Male or female ≥ 18 years and <80 years.
- Tumor assessable by RECIST v1.1, Scher Cheson 2008 or 99.
- At least 28 days after completion of prior treatment (radiotherapy, systemic chemotherapy or major surgery).
- Patient who recovered from any prior toxicity ≤ grade 1.
- WHO 0-1 in the 7 days before inclusion.
- Neutrophils ≥ 1500/mm3, Platelets ≥ 100 000/mm3.
- Total bilirubin and serum creatinine within normal limits (≤ 1.5 ULN), creatinine clearance ≥ 40 ml / min.
- AST / ALT ≤ 1.5 ULN (≤ 5 ULN if liver metastasis).
- Normal thyroid function.
- Normal coagulation: TP ≥ 70%.
- Life expectancy upper than 3 months.
- HAD score <13.
- Negative pregnancy test for women likely to be pregnant within 7 days before inclusion.
- Effective contraception for the duration of treatment (for both sexes in childbearing or reproductive age): mechanic contraception method should always be used in combination with other contraceptive methods (eg, oral or other hormonal contraceptives). Because of long half-life of efavirenz, it is recommended to use adequate contraceptive measures for 12 weeks after stopping treatment with efavirenz.
- Informed consent signed and dated by the patient or his legal representative before the establishment of any specific procedure to the study.
- Clinical examination and laboratory tests made within 7 days before enrollment and start of treatment.
- Initial assessment and radiological CT / or MRI performed within 30 days before enrollment.
- Patients potentially compliant with treatment and follow-up study.
- Ability to swallow capsules or tablets.
- Patients insured by a social security system.
Exclusion Criteria :
- Patient with pancreatic cancer.
- Presence of active or symptomatic cerebral localization (known).
History of another cancer except:
- cancer occurred more than five years and considered in complete remission
- in situ cervix carcinomas,
- cutaneous basal cell carcinomas.
- Current major depressive state (screening by HAD scale total score ≥ 13).
- Patients with history of depressive disorders, suicide attempts, addiction or other psychiatric disorders.
- Concomitant use of terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bepridil, alkaloids of ergot, voriconazole, mixing St. John's Wort.
- Patients treated with anti-vitamin K. Treatment with low molecular weight heparin are allowed.
- Known efavirenz hypersensitivity or to any of its excipients.
- Severe renal impairment.
- Severe hepatic impairment.
- Yellow fever vaccine (yellow fever).
- Pregnant or lactating.
- Presence of toxicity> 1 according to the criteria CTCAE V4.0, due to prior cancer therapy.
- Recurrent diarrhea which can interfere with drug absorption capacity.
- Patient included in another biomedical research on a drug within 30 days of inclusion.
- Patient who previously participated in this study.
- Patient, who for reasons psychological, psychiatric, social, family or geographical could not be treated or monitored regularly by the criteria of the study, patients deprived of liberty or under tutorship.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Efavirenz: 600 mg
Cohort 1 : Participants received 600 mg of Efavirenz (oral / once a day), until progression or toxicity.
|
Efavirenz 600 mg (oral daily intake)
|
Experimental: Efavirenz: 1200 mg
Cohort 2 : Participants received 1200 mg of Efavirenz (oral / once a day), until progression or toxicity.
|
Efavirenz 1200mg (oral daily intake)
|
Experimental: Efavirenz: 1800 mg
Cohort 3 : Participants received 1800 mg of Efavirenz (oral / once a day), until progression or toxicity.
|
Efavirenz 1800mg (oral daily intake)
|
Experimental: Efavirenz: 2200 mg
Cohort 4 : Participants received 2200 mg of Efavirenz (oral / once a day), until progression or toxicity.
|
Efavirenz 2200mg (oral daily intake)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) of Efavirenz
Time Frame: Up to 28 days for each dosing cohort
|
MTD was determined by testing increasing doses up to 3000 mg (oral daily intake). The dose escalation scheme is the continual reassessment method likehood approach (CRML) described by O'Quigley and Shen [O'Quigley et al. Biometrics 1996]. MTD reflects the highest dose of drug that did not cause a Dose-Limiting Toxicity (DLT) in > 25% of participants. A DLT was any drug-related toxicity with grade ≥ 3 according to NCI-CTCAE v4.0 (except alopecia, nausea and vomiting, regardless of grade), any drug-related toxicity, regardless of grade, who led a treatment delay> 14 days, a score ≥ 19 for the Hospital Anxiety And Depression Scale (HAD) during treatment. |
Up to 28 days for each dosing cohort
|
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
Time Frame: Up to 28 days for each dosing cohort
|
A DLT was any drug-related toxicity with grade ≥ 3 according to NCI-CTCAE v4.0 (except alopecia, nausea and vomiting, regardless of grade), any drug-related toxicity, regardless of grade, who led a treatment delay> 14 days, a score ≥ 19 for the Hospital Anxiety And Depression Scale (HAD) during treatment.
|
Up to 28 days for each dosing cohort
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
12-week Objective Response Rate
Time Frame: up to 3 months after first adminitration of Efavirenz
|
Objective response is defined as complete or partial response (CR, PR) using the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Objective reponse rate is calculated as the number of patients with objective reponse divided by the number of alive patients.
|
up to 3 months after first adminitration of Efavirenz
|
12-week Non-progression Rate
Time Frame: Evaluated up to 3 months after first administration of Efavirenz
|
Non progression is defined as complete or partial response (CR, PR) or stable disease (SD), using the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Non-progression rate is calculated as the number of alive and progression free patients divided by the number of patients.
|
Evaluated up to 3 months after first administration of Efavirenz
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Guilhem Roubaud, MD, Institut Bergonié
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Lymphoma, Non-Hodgkin
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Efavirenz
Other Study ID Numbers
- IB2011-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin's Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingNon-Hodgkin Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States
-
Immune DesignMerck Sharp & Dohme LLCTerminatedFollicular Low Grade Non-Hodgkin's Lymphoma
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
Haihe Biopharma Co., Ltd.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryUnited States, China
-
University Health Network, TorontoCompletedHodgkin's Lymphoma | Non Hodgkin's LymphomaCanada
-
Tarapeutics Science Inc.RecruitingAdvanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma RefractoryChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
Hoffmann-La RocheCompletedDiffuse Large B-Cell Lymphoma, Non-Hodgkin's LymphomaHong Kong, Germany, Philippines, Taiwan, Turkey, Canada, Australia, Austria, New Zealand, Thailand, Hungary, Italy, Korea, Republic of, Romania, Netherlands, Brazil, Indonesia, Croatia, Egypt, Portugal, Sweden, Colombia, Argentina, De... and more
-
SCRI Development Innovations, LLCBiogenCompleted
-
Auxilio Mutuo Cancer CenterCompletedRefractory Aggressive Non-Hodgkin's Lymphoma | Relapsing Aggressive Non-Hodgkin's Lymphoma
Clinical Trials on Efavirenz 600mg
-
Shanghai Public Health Clinical CenterNot yet recruitingHIV Infections | Tuberculosis
-
Peking Union Medical College HospitalUnknownHIV/AIDS | Mental ImpairmentChina
-
Spinifex Pharmaceuticals Pty LtdSyneos HealthWithdrawn
-
MyMD Pharmaceuticals, Inc.CompletedFrailty | Sarcopenia | AgingUnited States
-
Elif OralCompletedFatty Liver | Hypertriglyceridemia | NASH - Nonalcoholic Steatohepatitis | Familial Partial LipodystrophyUnited States
-
Kirby InstituteCompleted
-
I-Mab Biopharma HongKong LimitedCompletedActive Ulcerative ColitisChina, Taiwan, Korea, Republic of
-
Yungjin Pharm. Co., Ltd.CompletedDry Eye SyndromeKorea, Republic of
-
Ewha Womans UniversityCompletedHealthy Adults With Subjective Memory ComplaintsKorea, Republic of
-
National Institute of Allergy and Infectious Diseases...Not yet recruitingPregnancy | HIV-1-infection | PostpartumUnited States, South Africa